Journal of Contemporary Dentistry

Register      Login

VOLUME 5 , ISSUE 1 ( January-April, 2015 ) > List of Articles

RESEARCH ARTICLE

Awareness of Bisphosphonate Use and Its Dental Complications among the Dental Practitioners

Imran Khalid, Jyotsna Galinde, Sunil Sidana, Gauri Kokane

Citation Information : Khalid I, Galinde J, Sidana S, Kokane G. Awareness of Bisphosphonate Use and Its Dental Complications among the Dental Practitioners. J Contemp Dent 2015; 5 (1):1-6.

DOI: 10.5005/jp-journals-10031-1095

License: CC BY-ND 3.0

Published Online: 01-04-2015

Copyright Statement:  Copyright © 2015; The Author(s).


Abstract

PDF Share
  1. Drug treatment UK National Osteoporosis Society. Retrieved 7 Aug 2012.
  2. Bisphosphonate osteochemonecrosis (Bis-Phossy Jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005 May;63(5):682-689.
  3. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg 2012 Nov;41(11):1397-1403.
  4. The effect of alendronate on resorption of the alveolar bone following tooth extraction. Int J Oral Maxillofac Surg 2004;33:286-293.
  5. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011 Apr 1;48(4):677-692.
  6. Bench to bedside: elucidation of the OPG-rank-rankl pathway and the development of denosumab. Nat Rev Drug Discov 2012 May; 11(5):401-419.
  7. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008 Jun;19(6):733-759.
  8. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006 Oct 15;12(20 Pt 2):62225-62305.
  9. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999 Jul;25(1):97-106.
  10. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005 Nov;63(11):1567-1575.
  11. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention and treatment. J Oral Maxillofac Surg 2007 Dec;65(12):2397-2410.
  12. Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006 Mar;35(3):155-160.
  13. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 2009 Feb;45(2):164-172.
  14. Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of two cases with clinical implications. Oral Surg Oral Med Oral Pathol Oral Radiol 2012 Feb;113(2):234-238.
  15. Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg 2013 Sep;71(9):1532-1540.
  16. Bisphosphonate-induced osteonecrosis of the jaw (ONJ). Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 2009 Mar;112(3):605-609.
  17. Bisphosphonaterelated osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 2008 Oct 1;26(28):4634-4638.
  18. Denosumab and antiangiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease. Anticancer Res 2013 May;33(5):1793-1797.
  19. The effects of osteoclast modifiers on the oral cavity: a review for prescribers. Curr Opin Support Palliat Care 2012 Sep;6(3):337-341.
  20. Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. J Oral Pathol Med 2012 Mar;41(3):214-221.
  21. The saxon bisphosphonate register-therapy and prevention of bisphosphonaterelated osteonecrosis of the jaws. Oral Oncol 2012 Apr;48(4):349-354.
  22. Bisphosphonates and osteonecrosis of the jaw. J Am Geriatr Soc 2011 Dec;59(12):2350-2355.
  23. Oral health considerations in older women receiving oral bisphosphonate therapy. J Am Geriatr Soc 2011 May;59(5):916-922.
  24. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2011 Nov;142(11):1243-1251.
  25. Bisphosphonate osteonecrosis of the jaw—a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention. Br J Oral Maxillofac Surg 2011 Jun;49(4):251-257.
  26. Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery? Lasers Med Sci 2011 Nov;26(6):815-823.
  27. Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. Oncologist 2010;15(11):1147-1158.
  28. Bisphosphonateassociated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment. Breast 2009 Aug;18(4):213-217.
  29. Incidence of bisphosphonate- associated osteonecrosis of the jaws in breast cancer patients. Cancer 2009 Apr 15;115(8):1631-1637.
  30. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009 Mar;36(3):478-490.
  31. Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Int Med J 2009 May;39(5):304-316.
  32. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2008 Dec;139(12):1674-1677.
  33. ‘Bis-phossy jaws’-high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 2008 Mar; 36(2):95-103.
  34. American Society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007 Jun 10;25(17):2464-2472.
  35. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009 Jan;20(1):117-120.
  36. International consensus on diagnosis and management of osteonecrosis of the Jaw. J Bone Miner Res 2015 Jan;30(1):3-23.
  37. Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. Gen Dent 2013 Aug;61(5):33-38.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.